Advanced Search:
Equity Index

GNFT.PA - GENFIT

€3.34  0.03 (0.9%)

Updated: 11:48 May 5, 2024 EST

Next Session's AI Forecast

92.87%

Avg. Accuracy (AI)

€3.08

Next Week's AI Forecast

0%

Trend's Accuracy (AI)

€3.21

GENFIT's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

GENFIT - HISTORICAL DATA 6M

  • Last price

    €3.34

  • Daily change

    €0.03

  • Previous Close

    €3.31

  • Last Updated

    11:48 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
1 0.21 -0.04 0.05 -0.01

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
1.07 1.24 1.47 1.83 1.98

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
100% 100% 100% 52.27%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
3.3 1.85% 3.24 -0.31% 3.25 -1.52% 3.3

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
2 -1 2 66.67

GENFIT Technical Analysis News

GENFIT

Parc EurasantE
885, avenue EugEne AvinEe
Loos 59120
France
33 3 20 16 40 00
https://www.genfit.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 159
Description

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Corporate Governance

Genfit S.A.’s ISS Governance QualityScore as of May 1, 2024 is 5. The pillar scores are Audit: 9; Board: 7; Shareholder Rights: 5; Compensation: 4.

GENFIT'S HOLDERS RANK

List of holders with stock participation in GENFIT.

Holder Rank Holder Shares Date Reported % Out Value